Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now. On June 23, Immutep Limited (NASDAQ:IMMP) announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. This is the first-in-class LAG-3 agonist antibody for autoimmune diseases. The company stated that through the highest dosing level to date (0.9 mg/kg of IMP761), there were no treatment-associated adverse events in healthy participants.Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data

A business-person in a lab coat standing in front a microscope that displays a DNA strand.

Considering the encouraging efficacy and safety, Immutep Limited (NASDAQ:IMMP) is continuing with single ascending dose levels of 2.5, 7, and 14 mg/kg. The LAG-3 (lymphocyte-activation gene-3) immune checkpoint is a promising therapeutic target for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis in multiple publications. Immutep Limited (NASDAQ:IMMP) stated that IMP761 is the first LAG-3 agonist antibody developed for potentially treating these large and growing disorders, each of which showcases multi-billion-dollar markets, and several other autoimmune diseases.

Through enhancing the “brake” function of LAG-3 in order to silence the dysregulated self-antigen-specific memory T cells, IMP761 has been designed in a way that targets the cause of autoimmune diseases and restores balance to the immune system.

Immutep Limited (NASDAQ:IMMP) is a late-stage biotechnology company engaged in developing novel immunotherapies for cancer and autoimmune diseases.

While we acknowledge the potential of IMMP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMMP and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.

View Comments